Medical Device Marketing Glossary

What it means. Most Class II medical devices reach the U.S. market through the 510(k) pathway. The applicant compares the new device's intended use, technology, and performance to a predicate, and the FDA either issues a clearance letter or a request for more data. A 510(k)-cleared device is "FDA-cleared," not "FDA-approved."

Why it matters for marketing. Every marketing claim has to match the cleared indication for use exactly. That's the substantiation ceiling. Substantial-equivalence framing ("just like the leading device") is fine in regulatory submissions but should not be exaggerated in promotional copy, where any superiority implication invites both FDA and FTC scrutiny.

In practice: When a client clears a new device, every ad headline, web page, and trade show graphic gets reviewed against the cleared indication for use before launch.

What it means. The AKS (42 U.S.C. § 1320a-7b(b)) applies to medical device manufacturers any time they offer remuneration (cash, meals, travel, "consulting" fees, free product, hotel stays) to a healthcare provider who could influence purchasing or referrals. Each violation is a felony punishable by up to $100,000 in fines and up to 10 years of imprisonment, plus mandatory exclusion from federal health care programs. The OIG can also pursue civil penalties of up to $50,000 per kickback plus three times the remuneration. Safe harbors exist for specific arrangements (personal services, equipment leases, GPO fees) but only if every requirement is met. The Stark Law (42 U.S.C. § 1395nn) is the physician self-referral counterpart and frequently applies to the same fact pattern.

Why it matters for marketing. Any sponsorship, gift, sample program, speaker fee, advisory board honorarium, dinner, or training-event hospitality intended to influence HCP purchasing is potential AKS exposure. The marketing question is not "can we pay for this?" It's "is this structured inside a written, fair-market-value agreement that fits a safe harbor?" Marketers who structure speaker programs, KOL engagements, or proctoring events should route every contract through regulatory before booking.

In practice: Sponsoring a surgeon's airfare and hotel for a "training event" is the textbook scenario marketers must structure carefully, log under Sunshine, and route through fair-market-value pricing.

What it means. CE marking certifies that a medical device meets the General Safety and Performance Requirements of the EU Medical Device Regulation. For most Class IIa, IIb, and III devices, a Notified Body audits the manufacturer's quality system and technical documentation before the mark can be applied. CE marking is required regardless of where the manufacturer is based, a Tennessee company selling into Germany needs it.

Why it matters for marketing. CE Mark status gates international market access, which gates international campaign timing. Marketing materials for the EU must show the CE mark and the four-digit Notified Body number, and EU-region claims must match the EU technical file (which often differs from the FDA submission). Running one global campaign across both regions almost always means watering claims down to the most restrictive region or building separate decks per region.

In practice: We maintain separate copy decks for the U.S. (FDA) and the EU (MDR) because ad copy compliant in one region routinely violates the other.

What it means. The FDA classifies every medical device by the risk it poses to the patient. Class I covers items like elastic bandages and exam gloves; most are 510(k)-exempt. Class II covers infusion pumps, surgical drapes, and most diagnostic imaging accessories, and typically requires a 510(k). Class III covers life-sustaining and high-risk devices like implantable pacemakers and HIV diagnostic tests, and almost always requires a Premarket Approval (PMA).

Why it matters for marketing. Classification determines the regulatory pathway. The pathway determines what's substantiated. What's substantiated determines what marketers can actually say. A Class II surgical instrument can be marketed with photography of the device in surgical use; a Class III implant typically cannot show patient outcomes without registry-level evidence. The class of the product is the first input to any claim ladder.

In practice: Before drafting a single line of copy, we confirm the device class, the regulatory pathway, and the cleared/approved indication for use. That determines what we can say.

What it means. These two phrases are not interchangeable, and the FDA enforces the distinction in promotional copy. Saying a 510(k)-cleared device is "FDA-approved" is a misbranding violation that frequently shows up in FDA Warning Letters. The correct copy for a 510(k) device is "FDA-cleared" or "cleared by FDA for [specific indication]."

Why it matters for marketing. This is the single most common piece of FTC- and FDA-actionable copy on medical device websites. "FDA approved" used loosely on a 510(k) device is both a regulatory issue (misbranding) and a truth-in-advertising issue (substantiation). Marketers should audit every page, ad, brochure, social post, and rep deck for the phrase before any campaign ships, and replace it with the accurate clearance status.

In practice: This is the first thing we audit on every client engagement, the exact phrase "FDA approved" vs. "FDA cleared" across the entire site, ad library, and sales collateral.

What it means. The FTC has parallel jurisdiction with the FDA over health-related advertising, especially for direct-to-consumer media. The FTC's "competent and reliable scientific evidence" standard means a marketing team needs the substantiation file before the ad runs, not after. Testimonial claims must reflect typical results or be disclosed as atypical. The FTC also polices native advertising, influencer disclosures, and "free trial" language in healthcare.

Why it matters for marketing. Every claim (performance, comparison, outcome, safety) needs a documented source attached to it before the campaign ships. The substantiation file is a marketing deliverable, not a regulatory afterthought. Comparative and superiority claims have the highest burden and the highest litigation risk. "FDA approved" copy on a 510(k) device is FTC-actionable in addition to FDA-actionable, and competitors increasingly use FTC complaints as a competitive lever.

In practice: Every aesthetic device or DTC campaign we run is built with a claim-substantiation grid (every line of copy mapped to its source, date, and reviewer) before media starts.

What it means. MDR replaced the older Medical Device Directive in May 2021. It tightened clinical evidence requirements, expanded the definition of a medical device to include certain cosmetic and aesthetic products, introduced the EUDAMED database for Unique Device Identifiers, and made post-market surveillance more rigorous. Manufacturers selling into the EU need an EU Authorized Representative, a CE-marked device, and marketing materials aligned to the device's MDR-classified intended purpose.

Why it matters for marketing. MDR sets the bar for what marketers can claim in EU/UK/EEA campaigns. Ad copy compliant in the U.S. routinely violates MDR claim rules in Europe. The EU technical file's intended-purpose language is usually narrower than what looks reasonable in a U.S. ad. International product launches need EU-specific copy decks, EU-region landing pages, and a regulatory review of every claim against the MDR-classified intended purpose, not the FDA-cleared indication.

In practice: We maintain separate copy decks for the two regions and route EU campaigns through a Notified Body-aware regulatory review before media launches.

What it means. Physicians can use a cleared device off-label in their own practice; manufacturers cannot promote it that way. Off-label promotion is the issue behind most FDA Warning Letters to device companies. Common traps: testimonial videos in which a surgeon mentions a use the device wasn't cleared for, social posts that reframe an indication, sales reps citing study data outside the cleared population, and influencer posts that drift outside the label. Two finalized FDA guidances bound what manufacturers may communicate: the June 2018 "Communications Consistent With the FDA-Required Labeling" final guidance (governing on-label promotional communications, with a three-factor consistency test) and the January 2025 "Scientific Information on Unapproved Uses" (SIUU) final guidance (governing firm-initiated communications to HCPs about off-label data, requiring truthful, scientifically sound, clinically relevant, peer-reviewed sourcing, kept presentationally separate from promotional materials). The Caronia (2nd Cir. 2012) line of cases narrowed FDA's prosecutorial reach for truthful off-label speech, but operating practice still defers to those two guidances.

Why it matters for marketing. This is the most consequential single line in medical device marketing: what marketers can and cannot say. Promotional copy, ad creative, social posts, sales rep talking points, KOL videos, podium decks, and influencer partnerships all live or die on whether they stay inside the cleared indication. "Scientific exchange" of off-label data is reserved for the medical-affairs / MSL function under the SIUU guidance. It is not a tool marketing teams can lean on. The safest and most durable posture for marketers: claim only what the cleared indication says, and route any reference to data outside the indication through medical affairs.

In practice: We review every testimonial transcript and case-study draft against the cleared indication for use before publication, and ask the surgeon to rerecord any phrase that drifts off-label.

What it means. PMAs require pivotal clinical trials, full quality-system inspection, and a substantial review cycle. Under the current MDUFA V commitment (FY 2023-2027), FDA's average Total Time to Decision goal is 285 calendar days for original PMAs and panel-track supplements received FY 2025 onward (290 days for FY 2023-2024 cohorts), with the FDA-only decision clock targeted at 180 FDA Days for 90% of submissions (or 320 FDA Days when an advisory committee is involved). Real-world averages can run materially longer when reviews require advisory-committee input or multiple deficiency cycles. Unlike a 510(k), a PMA produces an "approval", and the device can carry the phrase "FDA-approved." Approval can be conditioned on post-approval studies, label restrictions, and limited indications.

Why it matters for marketing. PMA-track devices justify a stronger evidentiary posture in copy. Claims should still match the approved indication, but the underlying clinical data is stronger and more defensible than 510(k) substantial-equivalence framing. Marketing planning for a PMA-track device usually begins 18 to 36 months before approval to align brand, KOL development, peer-reviewed publications, and reimbursement strategy with the expected label.

In practice: PMA-pathway devices warrant a full pre-approval marketing plan with a KOL bench, peer-reviewed publication strategy, and reimbursement materials, all in flight before the approval letter arrives.

What it means. Manufacturers report annually to CMS via the Open Payments program, and the data is searchable on a public CMS website. Reportable items include consulting fees, speaker honoraria, meals, travel, gifts above a de-minimis threshold, and ownership interests. For Program Year 2026, individual payments under $13.82 do not have to be reported unless aggregate annual transfers of value to the same covered recipient exceed $138.13, at which point every payment counts. Both thresholds are CPI-adjusted by CMS each year. The manufacturer is the reporting party and the one on the hook for accuracy.

Why it matters for marketing. Any payment, gift, food, or honorarium to an HCP from a marketing-funded activity is reportable above the de-minimis threshold and feeds the public Open Payments database. That changes how marketers should structure speaker programs, advisory boards, conference hospitality, KOL dinners, proctoring events, training-day travel, and even small things like sending lunch to a clinic. The marketing question is not just "can we afford it?" It's "how does this look on a public ledger searchable by patients, journalists, and competitors?" Marketers running KOL programs, advisory boards, or proctoring events need to log every transfer of value at the moment it happens.

In practice: We treat every dinner, speaker fee, and travel reimbursement at a KOL event as a Sunshine-reportable line item from the moment it's booked.

What it means. Accredited CME is awarded by ACCME-accredited providers. A device manufacturer can support CME through an unrestricted educational grant, but cannot control content, faculty, or learning objectives without losing accreditation and triggering AKS exposure. Industry-Supported Symposia at conferences are a common adjacent format that does allow manufacturer control but cannot be called CME.

In practice: When a client wants surgeon attendance at a training event, we structure it as either accredited CME (no manufacturer content control) or a non-CME industry symposium (full manufacturer control, no credit). Never both.

What it means. DTC is common for elective and aesthetic categories (cosmetic lasers, hearing aids, CPAP, glucose monitors, weight-loss devices) where the patient initiates the conversation with the doctor. DTC for prescription devices must comply with both FDA labeling rules and FTC truth-in-advertising rules, and is held to a higher disclosure standard than B2B marketing. Class III DTC carries additional risk and is rarely attempted.

In practice: An aesthetic device DTC campaign needs side-effect disclosures in every video, on every landing page, and within every social post, not just in the fine print at the bottom.

What it means. Most medical device marketing is DTP. Channels include physician trade publications, society conferences, peer-reviewed journals, surgeon-targeted LinkedIn, society email sponsorships, KOL content, and field sales. DTP messaging emphasizes clinical evidence, peer endorsements, procedural workflow, and reimbursement support, in roughly that order.

In practice: When a client says "we want to do digital marketing," 90% of the time the right answer is a DTP plan built around the conferences their target specialty attends.

What it means. HCP is the umbrella term used in regulatory and marketing language to cover everyone whose professional decision moves a device's volume. Different HCP segments behave very differently as buyers: surgeons typically have direct specification authority, while nurses and techs often have functional authority over consumables. A "physician" campaign and a "surgeon" campaign are not interchangeable.

In practice: We build the HCP target list per campaign by NPI number, specialty, procedure volume, and decision authority, not by generic "doctor" personas.

What it means. The federal National Assessment of Adult Literacy (NAAL, 2003) is still the only U.S. population-scale measurement of health-literacy proficiency. It found that only about 12% of U.S. adults have proficient health literacy, with another 53% at intermediate, 22% basic, and 14% below basic. Healthy People 2030 carries health literacy forward as a federal priority but reframes it around personal and organizational health literacy rather than re-running proficiency scoring. PIAAC Cycle 2 (2023) suggests general adult-literacy proficiency has slipped further since then, not improved. For DTC and patient-facing device marketing, this means a sixth-grade reading level, plain-language alternatives to medical terminology, visual explanations of mechanisms of action, and disclosures patients can actually parse. Low health literacy isn't a niche concern. It's the default audience condition.

In practice: We test patient-facing copy with a Flesch-Kincaid grade score and rewrite anything above 8th grade unless the device is for clinicians only.

What it means. ICD-10-CM (clinical modification) is maintained by CMS and the NCHS; CPT is maintained by the AMA. A device's path to reimbursement runs through getting clinicians a clean way to code the procedure that uses the device. New devices that don't fit existing CPT codes often need a Category III emerging-technology code, which requires a multi-year process of clinical evidence and AMA submission.

In practice: Our reimbursement collateral always includes the suggested ICD-10 + CPT pairing for the indication, plus the LCD (Local Coverage Determination) coverage map by region.

What it means. KOLs are not just famous surgeons. They are the people whose names appear on pivotal trials, whose podium presentations get cited, and whose adoption signals the rest of the specialty to follow. KOL programs include paid advisory boards, speakers' bureaus, podium presentations, training proctorships, and case-series publications. Every dollar paid is Sunshine-reportable, and every contract has AKS exposure. The best KOL program is built around clinical evidence, not just speaking fees.

In practice: We build a tiered KOL bench (national, regional, local) for every product launch and budget for 12 to 24 months of relationship-building before launch day.

What it means. MSLs are not sales reps. The legal distinction matters: under FDA enforcement policy, MSLs can engage in "scientific exchange" (including unsolicited communications about unapproved uses) while sales reps cannot. The current FDA framework rests on two finalized guidances: the June 2018 "Communications Consistent With the FDA-Required Labeling" final guidance (governing on-label promotional communications, with a three-factor consistency test) and the January 2025 "Scientific Information on Unapproved Uses" (SIUU) final guidance (governing firm-initiated communications to HCPs about off-label data, requiring truthful, scientifically sound, clinically relevant, peer-reviewed sourcing, kept presentationally separate from promotional materials). The Caronia (2nd Cir. 2012) line of cases narrowed FDA's prosecutorial reach for truthful off-label speech, but operating practice still requires strict role separation between MSLs and sales, separate reporting lines, and annual documented training. MSL teams typically partner with marketing on KOL development and clinical evidence dissemination.

In practice: We coordinate marketing campaigns with the MSL team's KOL map so we're not introducing a sales rep to a surgeon the MSL is mid-conversation with.

What it means. For device marketing, the journey map shows where the patient becomes "addressable" (a Google search, a referral, a community group, a screening event) and where the prescribing or implanting decision actually happens. The map is the basis for which channels get budget. Diagnostic devices buy at the symptom-search stage; implantables buy at the specialist-consult stage; consumables buy at the pre-op planning stage.

In practice: Every campaign starts with a one-page patient journey map that names the search query, the channel, and the decision-maker at each stage.

What it means. POC has been the fastest-growing category in diagnostics for a decade. POC marketing usually emphasizes turnaround time (minutes vs. days), workflow integration with the clinician's existing visit, reimbursement codes that stack with the visit, and the cost difference vs. a send-out lab. POC devices range from rapid antigen tests to handheld ultrasound to bedside hemoglobin analyzers.

In practice: A POC device's value proposition is almost always "minutes, not days," and the marketing copy should lead with that number.

What it means. Reimbursement strategy answers three questions: Will payers cover this? Under what code? At what rate? It involves payer mix analysis, Medicare LCD review, commercial payer policy tracking, dossier development, and HEOR (health economics and outcomes research). For a new device, reimbursement strategy can take 18 to 36 months and is typically led by a market-access team alongside marketing.

In practice: A device with no clean reimbursement path can have the best clinical data in its category and still fail to move volume. Marketing budget alone won't fix it.

What it means. Under value-based care, hospitals and ACOs are paid more for keeping patients healthy and less for repeat hospitalizations. Devices that reduce readmissions, shorten length of stay, prevent infections, or keep patients out of the OR have a stronger case under value-based reimbursement. Devices that depend on procedure volume face more friction. Marketing collateral for value-based environments emphasizes total cost of care, not just per-procedure cost.

In practice: When pitching to a hospital with significant ACO contracts, we lead with readmission and length-of-stay data, not procedure efficiency.

What it means. In medical device sales, no one person buys. The committee usually includes the specifying physician, the department chair, a value analysis lead, a supply chain or procurement officer, biomedical engineering, infection prevention if relevant, finance, and a C-suite sponsor for big-ticket capital. Each role has a different objection profile, and the marketing collateral has to speak to all of them. Not just the surgeon.

In practice: We build a multi-asset sales kit with a one-pager per stakeholder role, because the surgeon's pitch isn't the CFO's pitch.

What it means. C-suite involvement scales with deal size. A $2,000 disposable rarely sees a CFO; a $2 million capital purchase always does. Marketing to the C-suite is its own discipline, with executive briefings, roundtables, peer-to-peer events, and short, finance-led whitepapers replacing the clinical-evidence assets used with surgeons.

In practice: For capital-equipment deals, we build a CFO-specific economic model showing payback period and cost per case, separate from the clinical sales materials.

What it means. Most U.S. hospitals belong to one or more GPOs. To sell into those hospitals at scale, a manufacturer typically needs a GPO contract; without one, the deal often dies in supply chain. GPO contracts come with administrative fees paid by the supplier (typically 1.5% to 3% of contract volume, with 3% being the cap under the OIG GPO safe harbor at 42 CFR § 1001.952(j)) and are governed by an AKS safe harbor specifically for GPOs. GPO contracting cycles are long, and the pre-contract relationship-building runs through both clinical evaluation and supply-chain diligence.

In practice: Pursuing a GPO contract is a multi-quarter sales cycle, and the marketing assets needed (clinical evidence, economic analysis, references) often don't exist before a startup tries. Building them is half the work.

What it means. Administrator titles include Director of Surgical Services, Director of Materials Management, Director of Cardiology Operations, and equivalents. They sit between the C-suite and the clinical staff and often hold practical veto power over a purchase even after the surgeon has decided to use the device. Administrators care about utilization rates, contract terms, and predictability, not clinical novelty.

In practice: A surgeon can champion a device into the hospital, but the OR director can still kill the deal over storage footprint or sterilization workflow. We always have an admin-facing leave-behind.

What it means. The largest IDNs (HCA Healthcare, Ascension, CommonSpirit, Kaiser) operate hundreds of facilities and contract centrally. Selling to an IDN means selling once into the system office and then driving adoption across dozens of facilities. IDN-level contracts also mean IDN-level standardization committees, multi-site clinical evaluation, and committee-driven pricing.

In practice: A successful IDN win typically converts to 12-18 months of post-contract field marketing to drive site-by-site adoption. We plan that follow-on work into the launch budget.

What it means. Procurement officers run RFP processes, validate GPO contract pricing, handle vendor onboarding, and police against off-contract spend. They aren't clinicians, and clinical novelty doesn't move them. Pricing terms, contract reliability, supply security, and onboarding process do. The procurement officer is the most-overlooked stakeholder in early-stage device marketing.

In practice: We always include a vendor-onboarding one-pager (W-9, COI, certifications, fill rate, lead time) in the sales kit because procurement asks for it on day one.

What it means. The surgical staff cares about clinical performance, ergonomics, learning curve, and surgical workflow. The admin staff cares about cost, contract terms, training burden, sterilization workflow, and regulatory documentation. Most device marketing budgets get spent talking only to surgical staff. Then deals stall on the admin side. The fix is parallel campaigns with role-specific messaging.

In practice: Trade show booth strategy reflects this: clinical demos in front, value analysis collateral and procurement one-pagers in back, sales reps trained to identify which type of badge is walking in.

What it means. VAC review is the single most common point at which device sales stall in U.S. hospitals. Submissions typically require: clinical evidence summary, total cost of care comparison, training plan, sterilization and reprocessing instructions, in-service requirements, GPO/contract status, and clinical-champion sign-off. VAC committees meet monthly or quarterly. A weak submission gets tabled and reslotted, adding 60-180 days to the sales cycle.

In practice: Our VAC submission template runs to 14 sections and we work with the clinical champion to fill it out before the sales rep ever submits, the submission is the marketing asset.

What it means. A typical 10x10 booth at a mid-size medical conference runs $5,000-$15,000; a 20x20 island in a premium aisle at a major show like RSNA or HIMSS can run $50,000-$150,000 before build-out. Tiers also differ by who's selling: society-managed shows often have member discounts, while commercial shows like SXSW Health rarely do. Booth pricing is the floor of the conference investment, not the ceiling. Total cost typically runs 3-5x the booth fee once travel, build, staffing, and pre-show marketing are added in.

In practice: We model total conference cost (booth + build + travel + lead costs) before recommending a show, and reject booths whose total cost-per-qualified-lead exceeds the client's CPL ceiling.

What it means. Sponsorship tiers run from a few thousand dollars (conference bag insert) to hundreds of thousands (title sponsor of the keynote ballroom). Sponsorships are the highest-margin product the conference sells, so societies push hard. They are also where most conference budgets get over-spent on impression-based "branding" that doesn't generate qualified leads.

In practice: We say no to most sponsorships unless they put the brand in front of the buying committee at a moment of decision. A lanyard at a society show is rarely that.

What it means. This matters for who shows up at a booth. Exhibit-only badges are common for industry visitors, vendors, and procurement. Full-conference badges are held by clinicians earning CME and academic researchers. Lead retrieval data should always be filtered by badge type before reporting CPL or follow-up priority.

In practice: We split post-show lead reports by badge type. Full-conference attendees get the clinical-evidence follow-up; exhibit-only attendees get the procurement and operations follow-up.

What it means. ISS slots are bought from the conference society as sponsorship inventory. They give the manufacturer near-total control over speakers, content, and food service, and let the brand reach a captive clinical audience (typically 100-400 attendees) without competing for booth foot traffic. Because the manufacturer controls content, ISS sessions cannot be accredited as CME unless the manufacturer steps fully out of content control. Sunshine Act reporting still applies to any meals and travel funded.

In practice: An ISS slot at a society conference is one of the highest-conversion KOL launch tactics we run. But only if the manufacturer's clinical narrative is already ready to support 45 minutes of content.

What it means. Lead retrieval is sold separately from booth space at most conferences. The data structure varies: some shows return a name and email only, others return full demographics and qualification fields. Custom qualifying questions usually cost extra. Lead-retrieval data quality depends entirely on rep discipline at the booth. Scanning every walk-by inflates leads and wrecks ROI math.

In practice: We pre-train booth staff on a 30-second qualifying script and only scan badges that complete it, so the post-show file is genuinely qualified rather than warm-bodies-passing-by.

What it means. Most conference budget is spent on at-show (booth, build, staffing, travel) and most ROI is left on the table because pre- and post-show are underfunded. A useful rule: pre-show should account for 20-30% of total budget, at-show 50-60%, post-show 15-25%. Pre-show campaigns include targeted email to the registrant list, LinkedIn ads against the show's target audience, and personalized outreach to known accounts. Post-show is the second-most-important week of the campaign.

In practice: We start the pre-show campaign 60 days out, the post-show campaign within 48 hours of the show closing, and treat the booth as one of three deliverables, not the only one.

What it means. The scientific program is run by a society's program committee, separate from the exhibit hall. Manufacturers cannot pay to be on the scientific program; placement is earned through researcher submissions, peer review, and acceptance. Marketing leverages the scientific program by sponsoring the printed program book, supporting investigator-led posters and abstracts, and aligning ISS content with the program's themes.

In practice: Whenever a client has investigator-led research being presented, we plan the booth narrative around the poster's findings, so the trade-show story matches the science the audience just heard.

What it means. Trade show ROI is hard to calculate because medical device sales cycles are 6-18 months, so the leads from a March show convert through Q4 or later. The honest version of ROI uses a multi-quarter attribution window, a single qualified-lead definition, and a CPL cap that the client agreed to before the show. The dishonest version counts every badge scanned at the booth as a "lead."

In practice: We define the qualified-lead criteria in writing before the show ships and report ROI at 30, 90, and 180 days post-show, not "leads scanned" on closing day.

What it means. ABM is the natural fit for medical devices because the universe of accounts is small (a few thousand hospitals, hundreds of IDNs) and the decision involves multiple stakeholders. ABM programs use intent data, account-level advertising, personalized landing pages, sales-coordinated outreach, and one-to-few content tailored to each account's procedure mix and existing vendors. The ROI is measured in pipeline against named accounts, not in lead volume.

In practice: For a six-figure capital device, we run a 50-account ABM program with five custom landing pages per account, outbound sequences tied to NPI-level intent signals, and a dedicated SDR handoff.

What it means. FDA-compliant content has to reconcile two pressures: marketing wants the strongest possible claim; regulatory wants the safest possible claim. The middle ground is a claim ladder: every line of marketing copy maps to a substantiation source (the cleared label, the pivotal trial, a peer-reviewed publication, a registry). Content that can't cite is content that gets cut.

In practice: We maintain a claim-substantiation grid for each client (every marketing claim, the source, the date, the regulatory reviewer's initials) so a Warning Letter never finds an orphaned claim.

What it means. Long-cycle sales need marketing that nurtures buyers across many months, not "leads now." This means evergreen content, multi-touch nurture sequences, account-level intent monitoring, and patience with attribution. The marketing measure isn't "did this lead convert?" It's "did the account move to the next stage?"

In practice: We track marketing-influenced pipeline at the account level and report the stage progression each quarter, not the cost per MQL.

What it means. MDx marketing differs from device marketing in two important ways. First, the regulatory regime is the FDA's CDRH IVD division (and the EU IVDR in Europe), with different submission rules. Second, the buyer is usually a clinical lab director, not a surgeon. Lab directors care about throughput, sample type, validation work, and integration with their existing analyzer footprint, not surgical workflow.

In practice: An MDx campaign's hero asset is usually a verification & validation summary, not a surgeon testimonial.

What it means. Medical writing requires a level of subject-matter literacy that most marketing copywriters don't have. It overlaps with marketing in clinical evidence content, white papers, KOL-bylined articles, and evidence binders, but it has its own conventions (AMA style, citation discipline, IMRAD structure for original research). When marketing teams skip medical writers and have generalist copywriters draft clinical content, regulatory rejects it, KOLs decline to put their name on it, and the resulting asset has to be rewritten.

In practice: We pair Sage with Morgan and Regan on every clinical-evidence asset so the voice is readable, the science is right, and the regulatory exposure is zero.

What it means. MedTech PR runs across three audiences: trade media (MedTech Dive, Endeavor's Mass Device, Becker's), business media (WSJ, Bloomberg, Reuters), and clinical media (specialty journals and society publications). Each cares about a different angle on the same announcement: the trade press wants the device and the market context, the business press wants revenue and competitive positioning, the clinical press wants the data. A single press release rarely lands in all three.

In practice: We draft three angles per announcement (clinical, business, trade) and pitch them as three different stories to three different reporters.

What it means. Thought-leadership programs combine bylined articles, podcast appearances, conference podiums, peer-to-peer events, and LinkedIn content. The manufacturer's role is to fund time, build the editorial calendar, and run distribution. The physician's role is to bring the clinical credibility and the actual point of view. The hardest part is the manufacturer staying out of the content.

In practice: We separate content control entirely (the physician owns the editorial line) from production support (we own scheduling, design, and distribution), and that separation is documented in the contract for AKS and Sunshine reasons.

What it means. Surgeons are a small, time-poor, peer-driven audience. Effective surgeon-targeted content shows the device in clinical context (cadaver lab, OR, surgical animation), references peer-reviewed evidence by name, and respects surgical workflow. Generic B2B content doesn't perform: surgeons skip stock photography of "doctors smiling at clipboards" and bounce off any article that doesn't get to the procedure within the first paragraph.

In practice: Our surgeon content rules: real OR or cadaver visuals, the named procedure in the first sentence, citations to peer-reviewed studies, and never longer than the surgeon would read on a phone between cases.

What it means. Surgical video shows what a device actually does in the OR: tissue interaction, ergonomics, time-in-procedure, and outcome. It is more persuasive to surgeons than any other format. It also has to be cleared through the surgeon's institution, with patient consent (for live) or no patient (for cadaver), and edited carefully to avoid off-label drift. Distribution is on YouTube, the manufacturer's site, and society channels.

In practice: We budget surgical video as the centerpiece of every surgeon-focused launch and treat all other content as the campaign that drives traffic to the video.

What it means. Webinars in medtech work best when they are clinical-evidence-led and KOL-fronted, not sales-deck-led. A useful pattern: 35 minutes of KOL clinical content, 5 minutes of device-in-use video, 15 minutes of moderated Q&A, no sales pitch. Promotion runs against society lists, LinkedIn, and email. Post-event, the recording becomes a long-tail asset and the registration list becomes the nurture pool.

In practice: We treat the webinar registration list as more valuable than the live attendance. The no-shows still see the recording, and the registration intent is a sales signal.

What it means. AI search visibility is its own discipline distinct from classic SEO. AI engines pull from authoritative pages, structured glossaries, schema markup, llms.txt files, and verifiable third-party citations. A site with strong Google rankings can still be invisible to ChatGPT if its content isn't structured for extraction. Visibility is binary at the engine level (cited or not cited) and additive across engines.

In practice: We run a quarterly AI Visibility audit for each client, prompting the major engines on the queries we want to rank for and tracking citation rate over time.

What it means. In healthcare paid search, CTR sits in a wide range: branded searches can hit 15-30%, while broad clinical category terms run 1-3%. Low CTR on a high-intent keyword usually means the headline isn't matching the searcher's expectation, the ad copy is generic, or the page promises something the title doesn't. CTR is a leading indicator for landing page quality and for Google Ads Quality Score.

In practice: When CTR collapses on a previously-strong query, we check the SERP for new competitors before assuming the ad copy is broken.

What it means. CRO in medical devices works differently than ecommerce CRO. The conversion event is rarely a purchase; it's a high-intent contact form completion. Wins come from clarifying the offer, removing friction in the form, adding peer evidence, and matching the page's promise to the traffic source. A 3% to 5% CRO win in medtech can equal hundreds of thousands of dollars in pipeline because each conversion is high-value.

In practice: We run sequential A/B tests on the demo request form, the hero headline, and the form-field count, in that order. Those three changes account for most of the lift we see across clients.

What it means. FAQPage schema is among the highest-leverage tactics for healthcare SEO right now: it makes content extractable for "people also ask," AI Overviews, and chatbot answers. It needs to be placed on pages with genuine Q&A content. Using FAQPage schema cosmetically (without real Q&A on the page) violates Google's structured-data guidelines and can trigger manual penalties.

In practice: For INFAB radiation-protection product pages, we ship FAQPage schema for the buyer's actual technical questions (cleaning, Pb equivalence, sizing) and have measured both organic CTR and AI-citation lift.

What it means. Geo-targeted campaigns matter most for hospital-system marketing (HCA Mountain Division, Vanderbilt referral region), regional medical device manufacturers, and city-keyword SEO ("Nashville healthcare marketing agency," "Memphis orthopedic surgeon"). Implementation runs through Google Ads geo-bidding, location pages on the site, GMB optimization for clinical practices, and city-level content. Done well, geo-targeting beats national campaigns on cost per qualified lead inside the target geography.

In practice: Buzzbox's own "Nashville healthcare marketing agency" positioning is a deliberate geo-targeted strategy. The term has buyer intent and far less competition than "healthcare marketing agency."

What it means. Google ranks healthcare content under stricter quality guidelines than other categories ("Your Money or Your Life" content). Authoritative authorship (named clinicians, credentials, citations), clear sourcing, and conservative claims all factor in. Healthcare SEO also has to play inside FDA labeling. Pages that rank for off-label searches can become regulatory exposure, not just SEO upside.

In practice: For every healthcare client, we audit the rankings against the cleared indication for use first, then optimize. Never the other way around.

What it means. In medical device marketing, organic and paid serve different roles. Organic builds long-term authority and is the substrate for AI search visibility. It compounds over years. Paid is fast, controllable, and ideal for product launches, conferences, and time-bound campaigns, but stops the day the budget stops. Most well-run medtech programs spend roughly 60% on organic content and SEO and 40% on paid, but the right ratio depends on launch timing and competitive intensity.

In practice: When a client wants "results in 30 days," paid is the only honest answer. When they want a defensible position 18 months from now, organic is.

What it means. Medical device catalogs are different from consumer catalogs. They have to handle 200-1000+ SKUs across multiple product families, technical spec tables, regulatory marks (FDA, CE, ISO), reference photography that holds up at print-quality, and a way for procurement to cross-reference part numbers fast. Catalogs are still used at trade shows, on sales calls, and as the trusted reference for procurement teams onboarding a new vendor.

In practice: For INFAB, we maintain a 200-page bilingual catalog that doubles as the product reference for procurement and the brand showcase at every trade show. The digital version backstops the print run for sales rep iPads.

What it means. Selling regulated devices online means: license validation for prescription-only devices (state license, NPI, DEA where relevant), tiered pricing for facility vs. distributor vs. consumer, contract pricing for GPO members, sales-tax handling across 50 states, and product data that meets FDA labeling at the SKU level. The platform usually has to integrate with the manufacturer's ERP for inventory and order routing.

In practice: Most medical ecommerce builds aren't ecommerce projects. They're ERP-integration projects with a storefront on top.

What it means. For most medical device manufacturers above startup size, the ERP (SAP, NetSuite, Microsoft Dynamics, Epicor) is the source of truth. Not the website. Marketing systems that don't integrate end up with stale prices, wrong inventory, and customer data that doesn't match what sales sees. Integration usually runs through middleware (Celigo, Workato, Boomi) and requires defined sync schedules and conflict-resolution rules.

In practice: Before launching any new ecommerce site for a medical device manufacturer, we map the ERP integration points and write the data sync rules. That work is often the longest line item in the project plan.

What it means. RFQ is the dominant transactional flow in B2B medical supply. The manufacturer's website rarely shows transactional pricing; instead, a "Request a Quote" form, a CSV upload, or an account-portal flow captures the line-item request and routes it to the inside sales team. RFQ response speed (turnaround under 24 hours) is one of the top differentiators procurement teams cite.

In practice: We design RFQ workflows so that procurement can paste a CSV of part numbers and get an automated quote inside the hour for in-stock items, with humans only handling exceptions.

What it means. A single lead apron product line can fan out to 60+ SKUs across sizes, lead-equivalence levels, color, material, and accessory bundles. A spinal-implant line can run to thousands of SKUs across vertebral level, screw size, rod length, and material. SKU complexity drives catalog design, ecommerce site architecture, ERP integration scope, and how the marketing team thinks about featured-product strategy. Hiding the complexity from the buyer is the design goal.

In practice: Our INFAB site uses a configurator-first flow on apron pages so the buyer answers three or four questions and lands on a specific SKU, instead of paging through 60 variants.

What it means. AEO and SEO overlap, but the optimization targets are different. SEO targets a ranked list and a click; AEO targets a citation inside an AI-generated answer and the trust the user puts in that citation. AEO winners tend to be: pages with clear definitions, structured Q&A, schema markup, named authors with credentials, and content that's quotable in a single sentence. AEO traffic is small in volume relative to organic search but high-trust. Users who arrive via an AI citation often arrive having already half-decided.

In practice: We design every Buzzbox content page to answer a specific "what is X?" question in the first 50 words, because that's the chunk an AI engine quotes.

What it means. AI Overviews summarize the SERP in a paragraph or two and link out to the sources used. They've reduced classic blue-link CTR in many categories and increased the value of being cited in the overview itself. Citation in an AI Overview depends on having authoritative, well-structured content, with key facts clearly extractable in the page's first hundred words and supported by schema.

In practice: When a client's category gets an AI Overview that doesn't cite them, we audit the cited sources to see what they're doing structurally and update our pages to match the extraction pattern.

What it means. A citation is more valuable than a ranking in most cases: it carries implicit endorsement from the AI engine, and users who click through arrive primed by the AI's framing. Citations track per-engine (a brand can be cited heavily on Perplexity and absent from ChatGPT) and per-query. Tracking requires running prompts manually or through a tool that probes engines on a schedule.

In practice: We track the top 25 buyer queries for each client across four engines weekly and chart citation rate as a primary KPI alongside organic rankings.

What it means. llms.txt is an emerging convention, not (yet) an enforced standard. The format lists site facts, services, key blog posts, case studies, and contact info in markdown. AI engines that respect the file use it as a structured map of the site and as a citation source. Buzzbox publishes its own llms.txt (and a fuller llms-full.txt) at the site root.

In practice: Every Buzzbox client we audit gets an llms.txt within the first 60 days; the cost is hours of work and the upside is being legible to engines that are now driving real traffic.

What it means. Schema is the lingua franca of structured data. Common types in medtech: Product and MedicalDevice for product pages, Organization and LocalBusiness for the company, Article for blog content, FAQPage for Q&A, DefinedTermSet for glossaries like this one, BreadcrumbList for navigation. Schema doesn't make a page rank, but it makes a page legible. And legibility is the precondition for AI citation.

In practice: Every page we ship has a JSON-LD schema block matched to its content type, and every glossary entry on this page is a DefinedTerm so the entire glossary is machine-extractable.